Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

493
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
493
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

80
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
80
Continuing Care01:25

Continuing Care

1.6K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

British journal of haematology·2026
Same author

Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.

HemaSphere·2026
Same author

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

American journal of hematology·2026
Same author

Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.

Experimental hematology & oncology·2026
Same author

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Blood advances·2026
Same author

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.7K

Cuidados paliativos para el tratamiento de pacientes con trasplante de células madre hematopoyéticas alogénicas: una

Anne Pralong, Marco Herling, Udo Holtick

    Oncology research and treatment
    |August 28, 2025
    PubMed
    Resumen
    Este resumen es generado por máquina.

    Se debate la integración de los cuidados paliativos especializados (CPS) en el trasplante de células madre alogénicas. Si bien se apoya ampliamente para un mal pronóstico, su uso en casos de buen pronóstico es menos favorecido, lo que pone de relieve la necesidad de criterios de integración claros.

    Más Videos Relacionados

    Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
    08:05

    Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

    Published on: March 17, 2020

    8.0K
    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
    03:40

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

    Published on: December 8, 2023

    1.3K

    Videos de Experimentos Relacionados

    Last Updated: Sep 9, 2025

    Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
    11:55

    Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

    Published on: March 14, 2011

    14.7K
    Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
    08:05

    Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

    Published on: March 17, 2020

    8.0K
    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
    03:40

    Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

    Published on: December 8, 2023

    1.3K

    Área de la Ciencia:

    • Hematología
    • Cuidados paliativos
    • En el campo de la oncología

    Sus antecedentes:

    • La atención paliativa especializada (SPC) no se utiliza en el trasplante de células madre hematopoyéticas alogénicas (HSCT) a pesar de la alta carga de síntomas y mortalidad.
    • Es necesario comprender las perspectivas de los profesionales de la salud sobre la integración de la SPC en la atención de la HSCT.

    Objetivo del estudio:

    • Evaluar las opiniones de los hematólogos y las enfermeras sobre el momento y los modelos óptimos para integrar el RCP en la HSCT.
    • Explorar las preferencias para la integración del RCP en función del pronóstico del paciente.

    Principales métodos:

    • Se realizó una encuesta transversal multicéntrica con hematólogos y enfermeras.
    • Para evaluar las preferencias de integración del RCP se utilizaron viñetas que mostraban pacientes con pronósticos variables (buenos, ' cincuenta por ciento', pobres).
    • Se emplearon estadísticas descriptivas y pruebas inferenciales (Chi2/Fisher exactas, no paramétricas).

    Principales resultados:

    • Los encuestados se mostraron fuertemente a favor de la integración del RCP para un mal pronóstico (96%), pero en gran medida se opusieron a ella para un buen pronóstico (63%).
    • En cuanto a los pronósticos "cincuenta por ciento", los médicos no mostraron consenso, mientras que las enfermeras en general apoyaron la integración.
    • El modelo preferido fue la cogestión para necesidades específicas, con el deseo de contar con el apoyo del RCP en la discusión de cuestiones que ponen en peligro la vida.

    Conclusiones:

    • El estudio subraya la necesidad de desarrollar criterios precisos para la integración del RCP dentro de la trayectoria de la HSCT.
    • Las perspectivas multiprofesionales son cruciales para el establecimiento de estrategias eficaces de integración de la SPC en la HSCT.